Last updated: 25 days ago
AstraZeneca's RESOLUTE Trial Report: Fasenra for COPD Shows Promise but No Stat Significance
AstraZeneca's 6-K filing reveals the RESOLUTE Phase III trial results for Fasenra in COPD. The treatment showed numerical improvements but did not meet primary endpoint significance.